Xuanzhu Biology: The first patient enrolled in the Phase III clinical trial of esomeprazole sodium for the new indication of eradicating Helicobacter pylori.

Xuanzhu Biology announced that the innovative drug Anilazol Sodium Enteric-coated Tablets independently developed by the group for the eradication of Helicobacter pylori with a bismuth-containing regimen in Phase III clinical trials has successfully completed the enrollment of the first patient. This marks the official entry of this key registration clinical study into a substantial execution phase.